Faculty

Kristopher R. Bosse, MD

Assistant Professor of Pediatrics (Oncology)

Department: Pediatrics

Graduate Group Affiliations

Cell and Molecular Biology

Contact information

Children's Hospital of Philadelphia
3501 Civic Center Boulevard, CTRB 3050
Philadelphia, PA 19104

Office: 651-492-6726
Fax: 267-426-0685

Email:
bossek@email.chop.edu

Education:
BA (Biochemistry )
Bowdoin College, 2002.
MD (Medicine)
University of Pennsylvania School of Medicine, 2010.

Permanent link

> Perelman School of Medicine > Faculty > Details

Selected Publications

Turn, C, Wolpaw A, Bosse KR: Neuroblastoma. Ferri’s Clinical Advisor 2025.

Strijker JGM*, Pascual-Pasto G*, Kalmeijer YJ, Kalaitsidou E, Zhao C, McIntyre B, Matlaga S, Visser LL, Barisa M, Himsworth C, Shah R, Muller H, Schild LG, Hains PG, Zhong Q, Reddel R, Robinson PJ, Catena X, Soengas MS, Margaritis T, Dekker FJ, Anderson J, Molenaar JJ, Bosse KR*, Wu W*, Wienke J*. : Blocking MIF secretion enhances CAR T-cell efficacy against neuroblastoma. bioRxiv. 2024 Notes: doi: https://doi.org/10.1101/2024.04.05.588098 *these authors contributed equally.

Wolpaw A, Bosse KR. : Neuroblastoma. Ferri’s Clinical Advisor 2024.

Kim J, Vaksman Z, Egolf LE, Kaufman R, Evans JP, Conkrite KL, Danesh A, Lopez G, Randall MP, Dent MH, Farra LM, Menghani N, Dymek M, Desai H, Hausler R, Penn Medicine BioBank, Regeneron Genetics Center, Cancer Genomics Research Laboratory, Auvil JG, Gerhard DS, Hakonarson H, Maxwell KN, Cole KA, Pugh TJ, Bosse KR, Khan J, Wei JS, Maris JM, Stewart DR, Diskin SJ. : Germline pathogenic variants in 786 neuroblastoma patients. Journal of the National Cancer Institute. 1: 149-159, 2024.

Randall MP, Egolf LE, Vaksman Z, Samanta M, Tsang M, Groff D, Evans JP, Rokita JL, Layeghifard M, Shlien A, Maris JM, Diskin SJ, Bosse KR. : BARD1 germline variants induce haploinsufficiency and DNA repair defects in neuroblastoma. Journal of the National Cancer Institute 1: 138-148, 2024.

Pascual-Pasto G, McIntyre B, Giudice AM, Alikarami F, Morrissey A, Matlaga S, Hofmann TJ, Burgueño V, Harvey K,cMartinez D, Shah AC, Foster JB, Pogoriler J, Eagle RC, Carcaboso AM, Shields CL, Leahey AM, Bosse KR. : Targeting GPC2 on intraocular and CNS metastatic retinoblastomas with local and systemic delivery of CAR T-cells. Clinical Cancer Research 2024 Notes: In press.

Weiner AK, Radaoui AB, Tsang M, Martinez D, Sidoli S, Conkrite KL, Delaidelli A, Modi A, Rokita JL, Patel K, Lane MV, Zhang B, Zhong C, Ennis B, Miller DP, Brown MA, Rathi KS, Raman P, Pogoriler J, Bhatti T, Pawel B, Glisovic-Aplenc T, Teicher B, Erickson SW, Earley EJ, Bosse KR, Sorensen PH, Krytska K, Mosse YP, Havenith KE, Zammarchi F, van Berkel PH, Smith MA, Garcia BA, Maris JM, Diskin SJ. : A proteogenomic surfaceome study identifies DLK1 as an immunotherapeutic target in neuroblastoma. BioRxiv. Dec 2023 Notes: doi: 10.1101/2023.12.06.570390.

Giudice A, Pascual-Pasto G, Matlaga S, Schuerch P, Samanta M, Bosse K. : Development of murine Gpc2 CAR T cells and syngeneic preclinical models to identify mechanisms of immunotherapeutic resistance in neuroblastoma. Advances in Neuroblastoma Research Congress May 2023.

Schuerch P, Zecchino VP, McIntyre BC, Groff D, Shraim R, Garrigan E, Bosse K. : CHRNA3 as a super-enhancer-driven oncoprotein and potential immunotherapeutic target in high-risk neuroblastoma. Advances in Neuroblastoma Research Congress May 2023.

Giudice A, Pascual-Pasto G, Matlaga S, Rouin G, McIntyre B, Schuerch P, Bosse K.: Neuroblastoma extracellular vesicles contain GPC2 and activate GPC2 CAR T cells in an antigen-dependent manner. Advances in Neuroblastoma Research Congress May 2023.